Akebia Scores Another Potential Win in Kidney Disease!
Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical developing cutting-edge therapies for the treatment of patients with kidney diseases, announced the acceptance of the filing of its New Drug Application (NDA) for its lead product candidate, Vadadustat, a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, intended for...
